HCG (Pregnyl / Novarel / Choragon)
Human Chorionic Gonadotropin – LH structural analog, Leydig-cell LHCGR receptor stimulus. AAS-PCT bridge against testicular atrophy and for HPTA restart. Cross-frame: future peptide library will add `hcg-peptid` with fertility-clinic framing.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
WHAT IS HCG (PREGNYL / NOVAREL / CHORAGON)?
Detailed overview
HCG (Human Chorionic Gonadotropin) is a 244-amino-acid glycoprotein (α + β subunit), structurally an LH analog with ~80% sequence identity on the β subunit. Endogenous source: pregnancy placental syncytiotrophoblast → blood + urine (peak at weeks 8-12 of pregnancy). Clinical HCG sources: (1) urinary-extracted (uHCG) – purified from pregnant women's urine (Pregnyl Organon 1973, Novarel Ferring 1973, Choragon Ferring EU); (2) recombinant (rHCG / choriogonadotropin alfa) – Serono Ovidrel/Ovitrelle CHO-expressed, higher purity. Mechanism: Leydig-cell LHCGR receptor agonism → exogenous LH mimicry → testicular testosterone production. **AAS-PCT context**: HCG bridges the LH suppression window when the user's own pituitary still isn't secreting enough LH. Two main usage protocols: **mid-cycle HCG** (250-500 IU 2-3x/week throughout the AAS cycle – testicular atrophy prevention); **PCT-blast HCG** (1500-2500 IU EOD × 10-14 days after the last AAS pin, then transition to SERM PCT). **Cross-frame note**: this is the `-perf` suffix entry; the future peptide library batch will add the `hcg-peptid` entry (fertility-clinic framing – IVF male factor + secondary hypogonadism Rx context, IDENTICAL molecule, different narrative). WADA-banned year-round (S2 Peptide Hormones).
Mechanism
Leydig-cell LHCGR receptor agonist (LH structural analog, ~80% β-subunit identity)
Dosing (PCT-blast)
1500-2500 IU EOD × 10-14 days
Dosing (mid-cycle)
250-500 IU 2-3x/week
Half-life
uHCG: 24-36 h / rHCG (Ovidrel): 30-50 h
Legal status
FDA + EMA Rx (fertility indications), WADA S2 (banned in+out-of-competition)
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Estrogen elevation (via indirect aromatization of Leydig-derived testosterone): water retention, nipple sensitivity, gynecomastia flare, mood swings; AI co-administration (anastrozole) may be needed in gyno-sensitive users
- Leydig-cell LHCGR receptor desensitization / downregulation with prolonged high-dose use (>2500 IU EOD, >4 weeks) – paradoxically worsens testicular response and testosterone output
- Injection-site reactions (SC/IM): pain, redness, swelling, itching, occasionally a sterile lump at the injection site
- Androgenic side effects from elevated testosterone: acne, increased oiliness, hair thinning (in androgen-sensitive users), libido fluctuation
- Headache, fatigue, irritability, restlessness – common, usually mild and transient complaints
- Hypersensitivity / allergic reactions: rash, urticaria, rarely angioedema or anaphylaxis (especially with urine-derived uHCG products)
- Fluid retention and peripheral edema; in gyno-sensitive individuals estrogen-driven water retention can also raise blood pressure
Contraindications · 7
- Androgen-dependent tumor or suspicion thereof – prostate carcinoma or prior/active testicular (germ-cell) cancer: HCG stimulates androgen production and is itself a tumor marker, hence absolutely contraindicated
- Known hypersensitivity to HCG or any component of the preparation (e.g. benzyl-alcohol preservative)
- Pre-pubertal males – HCG can trigger precocious puberty and premature epiphyseal closure
- Unexplained vaginal/genital bleeding, or estrogen-/hormone-sensitive conditions where further estrogen elevation is hazardous
- Prolonged high-dose monotherapy (>4 weeks continuously) – to be avoided due to Leydig receptor downregulation and counterproductive testicular desensitization
- Active thromboembolic disease or high thrombotic risk – the estrogen rise can increase the risk of venous thromboembolism
- Untreated or active endocrine disease (thyroid or adrenal insufficiency, hyperprolactinemia, untreated ovarian cyst) – HCG not advised before stabilization
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Treatment of hypogonadotropic male hypogonadism: Case-based scenarios.
Crosnoe-Shipley LE, Elkelany OO, Rahnema CD, Kim ED
Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression.
Coviello AD, Matsumoto AM, Bremner WJ, Lewis EW, Anawalt BD, Wang C, Yan X, Page ST, Leung A, Berman N, Swerdloff RS
Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy.
Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI
Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone
Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E.
Telegram
Have a question about HCG (Pregnyl / Novarel / Choragon)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.